EZHIP/CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma

Keyphrases

• Upstream Open Reading Frame (uORF) 100%
• H3K27M 100%
• Polycomb Repressive Complex 2 (PRC2) 100%
• Oncohistone 100%
• Posterior Fossa Ependymoma 100%
• Chromosome X 100%
• Inhibitory Proteins 100%
• Posterior Fossa 50%
• Enhancer of Zeste Homolog 2 (EZH2) 50%
• Tumor 40%
• Ependymoma 30%
• H3K27me3 20%
• Histone 20%
• Methyltransferase Activity 20%
• Mechanism of Action 10%
• Overexpressing 10%
• Overexpression 10%
• Poor Prognosis 10%
• Diffuse Midline Glioma 10%
• Young children 10%
• Molecular Groups 10%
• Mass Spectrometry 10%
• Hypomethylation 10%
• Neurodevelopment 10%
• Functional Domain 10%
• Western Blot Assay 10%
• Immunocytochemistry 10%
• Infant Patients 10%
• Peptide Model 10%
• Peptide Sequencing 10%
• Derepression 10%
• Modeling Analysis 10%
• Novel Targeted Therapy 10%
• Inhibitory Mechanism 10%
• C-terminal Region 10%
• Trithorax 10%
• SET Domain 10%
• Oncogenic Mechanisms 10%
• Su(var)3-9 10%
• Enhancer of Zeste 10%

Biochemistry, Genetics and Molecular Biology

• Open Reading Frame 100%
• Polycomb Repressive Complex 2 100%
• X Chromosome 100%
• Transcription Factor EZH2 50%
• Methyltransferase 20%
• Histone 20%
• Enhancer Region 10%
• Mass Spectrometry 10%
• Histone H3 10%
• Nerve Cell Differentiation 10%
• C-Terminus 10%
• Peptide Sequence 10%
• Derepression 10%
• Immunocytochemistry 10%
• SET Domain 10%
• Lysine 10%
• Western Blotting 10%